European Primary Care Cardiovascular Society

Lowering remnants becomes more important, also in light of the obesity epidemic

3' education - June 19, 2019 - EAS 2019 - Prof. Børge Nordestgaard
EPCCS Annual CV Summit

New diagnostic algorithm and therapeutic options in HF management

5' education - Mar. 22, 2019 - Lisbon, Portugal - Peter van der Meer & Monika Hollander
EPCCS Annual CV Summit

Update on managing CV risk in diabetes: what's the evidence?

5' education - Mar. 22, 2019 - Lisbon, Portugal - Kamlesh Khunti & Richard Hobbs
EPCCS Annual CV Summit

Stroke prevention in atrial fibrillation

5' education - Mar. 21, 2019 - Lisbon, Portugal - Michaela Machácová & Richard Hobbs
EPCCS Annual CV Summit

Recent updates to the international Hypertension Guidelines - where do they vary and what should we agree in primary care?

5' education - Mar. 21, 2019 - Lisbon, Portugal - Richard McManus & Richard Hobbs
EPCCS Annual CV Summit

Multimorbidity, CV disease and polypharmacy

10' education - Mar. 21, 2019 - Lisbon, Portugal - Dr. David Silvério Rodrigues

Lifestyle improvement forms the basis of comprehensive ACC/AHA guideline for primary prevention

3' education - Mar. 20, 2019 - New Orleans, LA, USA - Dr. Amit Khera

Implementation of advice facilitated by new overarching recommendations in ACC/AHA primary prevention guideline

3' education - Mar. 20, 2019 - New Orleans, LA, USA - Donna Arnett, MD

84% True AF in those with irregular pulse detected with smartwatch in proof-of-concept study

3' education - Mar. 20, 2019 - New Orleans, LA, USA - Michael Valentine, MD

First ischemic events and recurrent events reduced with highly purified omega-3 fatty acid

3' education - Mar. 20, 2019 - New Orleans, LA, USA - Deepak L. Bhatt, MD

ESC/ESH Guidelines on management of hypertension: what's new?

3' education - Feb. 11, 2019 - Prof. Bryan Williams - London, UK

EPCCS

3' education - Feb. 8, 2019

EPCCS society: what is available for members?

3' education - Feb. 7, 2019 - Prof. Richard Hobbs, MD

May Measurement Month: Get involved to increase awareness on elevated blood pressure

3' education - Feb. 6, 2019 - Prof. Neil Poulter - London, UK

Primary prevention of CV events with aspirin: yes or no?

3' education - Jan. 31, 2019 - Prof. dr. Freek Verheugt - Amsterdam, The Netherlands

HFpEF: What is it & size of the problem

10' education - Aug. 27, 2018 - Prof. Adriaan Voors - Groningen, The Netherlands

HFpEF: Current and future clinical approaches to manage HFpEF

10' education - Aug. 27, 2018 - Burkert Pieske, MD - Berlin, Germany

HFpEF: What are the most likely pathophysiological mechanisms involved in the disease

10' education - Aug. 27, 2018 - Carolyn Lam, MD - Singapore

HFpEF: How to diagnose

10' education - Aug. 27, 2018 - Barry Borlaug - Rochester, MN, USA

Primary Cardiovascular Care in Spain (Spanish)

5' education - Jan. 10, 2019 - EPCCS Council Berlin - Francisco Javier Sanz Garcia

EAPC formulates preference for CV risk prediction tool for use in clinical practice

News - June 26, 2019

The European Association of Preventive Cardiology reviewed various online risk prediction algorithms and considers advantages and caveats, and gives guidance on which tool to use for which patient.

Original intensive glucose control does not result in CV benefit in T2DM after 15 years: no legacy effect

Literature - June 25, 2019 - Reaven PD, et al. - N Eng J Med 2019

In a follow-up study of VADT, original intensive glucose lowing over 5.6 years did not result in improved outcomes in T2DM patients vs. standard-therapy after 15 years, providing no evidence of a legacy effect.

Lowering remnants becomes more important, also in light of the obesity epidemic

EAS 2019 - Maastricht, The Netherlands

3' education - June 19, 2019 - EAS 2019 - Prof. Børge Nordestgaard
Professor Nordestgaard notes that the importance of remnant cholesterol is increasingly recognized, as it is causally related to risk of ischemic stroke, myocardial infarction and all-cause mortality.

EAS 2019 Professor Nordestgaard notes that the importance of remnant cholesterol is increasingly recognized, as it is causally related to risk of ischemic stroke, myocardial infarction and all-cause mortality.

Lipid-lowering drug prescription decreases with age but increases with frailty

Literature - June 18, 2019 - Kleipool EEF et al. - Age and Ageing 2019

Based on a large Dutch primary care database, lipid-lowering treatment declined with increasing age in subjects aged ≥70 years, with higher prescription in frail vs. non-frail older adults regardless of CVD at baseline.

CVD risk assessment model helps assess individual preventive treatment benefit

News - June 18, 2019

The LIFE-CVD model can assess 10-year and lifetime CVD risk and life-years gained free from CVD and the effect of interventions in apparently healthy people.

New diagnostic algorithm and therapeutic options in HF management

5' education - Mar. 22, 2019 - Lisbon, Portugal - Peter van der Meer & Monika Hollander
Professor Peter van der Meer & Monika Hollander consider new recommendations in the latest ESC Guidelines on diagnosis and treatment of patients with HF, and the role GPs may play in this process.

EPCCS 2019 Professor Peter van der Meer & Monika Hollander consider new recommendations in the latest ESC Guidelines on diagnosis and treatment of patients with HF, and the role GPs may play in this process.

Validated prediction score for incident HF can be used in primary care setting

Literature - June 17, 2019 - Khan SS et al., - J Am Coll Cardiol. 2019

The PCP-HF score provides sex- and race-specific estimates of 10-year risk of incident HF, based on risk factor information readily available in primary care setting.

EAS Debate on Lp(a) – Should we treat high levels or not?

News - May 29, 2019
By debating on whether high Lp(a) levels should be treated or not, Brian Ference and Sotirios Tsimikas critically reviewed the available evidence on the link between Lp(a) and CV risk.

EAS 2019 By debating on whether high Lp(a) levels should be treated or not, Brian Ference and Sotirios Tsimikas critically reviewed the available evidence on the link between Lp(a) and CV risk. With poll

Clinical interest in HDL is historically low, but continued research into HDL yields interesting results

News - May 30, 2019
Prof. Chapman is convinced that better understanding of HDL metabolism can lead to novel therapies, but we need to realize that it is much more complex than we have acknowledged thus far.

EAS 2019 Prof. Chapman is convinced that better understanding of HDL metabolism can lead to novel therapies, but we need to realize that it is much more complex than we have acknowledged thus far.

Analysis of 4S data suggest greater benefit of statin therapy in those with inherited high LDL

News - May 29, 2019
An analysis of the 4S trial data suggests that people with characteristics suggestive of FH, gain greater clinical benefit from statin therapy, in reducing events and mortality.

EAS 2019 An analysis of the 4S trial data suggests that people with characteristics suggestive of FH, gain greater clinical benefit from statin therapy, in reducing events and mortality.

Individuals with probable FH but no diagnosis have worse survival compared with those with an FH diagnosis

News - May 31, 2019
A UK study involving over 1.7 million health records in the general population suggests that a considerable number of people may have FH but are not diagnosed yet, leading to premature mortality

EAS 2019 A UK study involving over 1.7 million health records in the general population suggests that a considerable number of people may have FH but are not diagnosed yet, leading to premature mortality

Lowering of LDL-c with fixed combination of two non-statin cholesterol-lowering agents in high-risk patients

News - June 7, 2019
A fixed combination of bempedoic acid and ezetimibe lowered LDL-c at 12 weeks more than with the individual components, in high-risk patients not at LDL-c goal.

EAS 2019 A fixed combination of bempedoic acid and ezetimibe lowered LDL-c at 12 weeks more than with the individual components, in high-risk patients not at LDL-c goal.